Cas3 antimicrobial company acquires Epibiome tech

Locus Biosciences Inc. (Research Triangle Park, N.C.) acquired a phage discovery platform from fellow antibacterial company EpiBiome Inc. (South San Francisco, Calif.) in an all-stock deal. Locus declined to disclose financial terms.

Locus launched in 2015 to develop an antimicrobial platform that turns bacteria's natural CRISPR-Cas3 defense system against itself to eliminate specific pathogenic species while sparing human cells and the microbiome (see "Cutting Through Resistance")...